Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabete mellito, tipo 2 - farmaci usati nel diabete - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - vildagliptinum, metformini hydrochloridum - compresse rivestite con film - vildagliptinum 50 mg metformini hydrochloridum 500 mg, hydroxypropylcellulosum, magnesio stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talco, e 172 (giallo) e 172 (rosso), per compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - vildagliptinum, metformini hydrochloridum - compresse rivestite con film - vildagliptinum 50 mg metformini hydrochloridum 850 mg, hydroxypropylcellulosum, magnesio stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talco, e 172 (giallo), per compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - vildagliptinum, metformini hydrochloridum - compresse rivestite con film - vildagliptinum 50.00 mg metformini hydrochloridum 1000.00 mg, hydroxypropylcellulosum, magnesio stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talco, e 172 (giallo), per compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - vildagliptinum, metformini hydrochloridum - compresse rivestite con film - vildagliptinum 50 mg metformini hydrochloridum 500 mg, hydroxypropylcellulosum, magnesio stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talco, e 172 (giallo) e 172 (rosso), per compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - vildagliptinum, metformini hydrochloridum - compresse rivestite con film - vildagliptinum 50 mg metformini hydrochloridum 850 mg, hydroxypropylcellulosum, magnesio stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talco, e 172 (giallo), per compresso haze. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - vildagliptinum, metformini hydrochloridum - compresse rivestite con film - vildagliptinum 50.00 mg metformini hydrochloridum 1000.00 mg, hydroxypropylcellulosum, magnesio stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talco, e 172 (giallo), per compresso haze. - farmaco antidiabetico orale - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformina cloridrato - diabete mellito, tipo 2 - farmaci usati nel diabete - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.